Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000153319 | SCV000202799 | pathogenic | not provided | 2014-03-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002516076 | SCV003445309 | pathogenic | Fabry disease | 2022-06-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects GLA function (PMID: 19387866, 21598360, 22773828). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 167139). This missense change has been observed in individuals with Fabry disease (PMID: 7531540, 15091117, 33437642). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 244 of the GLA protein (p.Asp244Asn). |